The U.S. Food and Drug Administration (FDA) expert committee voted on October 26 local time to support the provision of Pfizer's new crown vaccine to children aged 5 to 11 under emergency authorization.
On the same day, the FDA expert committee voted for the provision of Pfizer vaccines to children aged 5 to 11 with 17 votes in favor, 0 votes against, and 1 abstention.
The expert committee believes that the benefits of providing new crown vaccines to children of this age in preventing new crown pneumonia outweigh the potential risks.
For the 5-year-old to 11-year-old group, Pfizer said it will provide two doses of the new crown vaccine, the dose is one-third of the adult.
Pfizer said that studies have shown that the dose is sufficient for vaccine protection and hopes to reduce side effects.
(Produced by Wu Rui)
Editor in charge: [Ji Xiang]